Clinical Trial 21589

• Overview

  Study Title:

  BASECAMP-1: An Observational Study Obtaining Solid Tumor Tissue from Subjects with Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing

  Summary:

  To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform leukapheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment.

  Objective:

  Primary Objectives: Subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of undergoing leukapheresis. Subjects who can enroll on an A2 CAR T-cell therapy study within approximately 12 months of undergoing leukapheresis. The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 18 months of undergoing leukapheresis. The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 24 months of undergoing leukapheresis. Subjects experiencing loss of heterozygosity of HLA-A*02. Secondary Objectives: Subjects who experience an adverse event (AE) related to leukapheresis. Subjects who experience a grade 4 toxicity related to leukapheresis. Exploratory Objectives: T-cell profiling of leukapheresis product. Biomarker analysis

• Inclusion Criteria

  Inclusion Criteria: Patients must fulfill all of the following screening criteria to be initially eligible for the study. Screening Inclusion Criteria: BCG unresponsive HG NMIBC (Defined in part 5.1) and healthy enough to participate:
  • Participants must have: a. Histologically confirmed urothelial cell NMIBC (T1, Ta, and/or Tis) and a. Bladder tumors with variant histology or mixed histology can be enrolled if the urothelial component is greater than 50% of the TUR specimen b. if Ta and T1, patients must have undergone complete restaging TURBT to confirm absence of muscle invasion (T2), however residual CIS is acceptable. a. This restaging can be considered the primary tumor harvest if patients have had a previous resection.
  • Have cytoscopic evidence of measurable disease. (There is no minimum measurement to be considered measurable disease. Any visible evidence is considered recurrence.)
  • A tissue specimen may be obtained which is appropriate for TIL preparation. The tissue may be collected through a procedure the patient otherwise requires for treatment purposes. Alternatively, and in consultation with a surgical specialist, a separate procedure of limited risk to the patient (such as a repeat bladder biopsy) may be performed specifically for tissue collection purposes.
  • Age ≥18 year
  • ECOG performance status 0-1
  • Participants must have adequate organ and marrow function in an assessment performed within 7 days (+ 3 day window) of enrollment as defined below: a. absolute neutrophil count ≥1,000/mcL b.platelets ≥100,000/mcL c. total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) or ≤ 3x ULN if confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology) d. AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN unless liver metastases are present, in which case it must be ≤ 5x ULN e. PT and PTT ≤ 1.5x institutional ULN f. serum creatinine 1.5 ≤ institutional ULN g. glomerular filtration rate (GFR) >60 mL/min h. albumin ≥ 2.5 g/dL i. hemoglobin ≥ 9.0 g/dL
  • Ability to understand and the willingness to sign a written informed consent document.

• Exclusion Criteria

  Exclusion Criteria:
  • Any previous treatment with intravesical chemotherapy within the previous 6 months.
  • Current or prior use of any immunosuppressive medications, such as corticosteroids, within 14 days before enrollment. a. Oral hydrocortisone, only for the purposes of a documented and confirmed adrenal insufficiency diagnosis, is permitted if ≤ 25 mg daily total dose. b. Inhaled, intranasal, or topical corticosteroids are permitted.
  • Current or prior use of anticancer therapy that has been shown to effect lymphocyte function before TIL collection.
  • Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than stable atrial fibrillation).
  • Patients known to be HIV positive, hepatitis B or C positive, or both RPR and FTA positive. (Hepatitis B surface or core antibody alone is not indicative of HBV infection).
  • Known history of previous tuberculosis
  • Receipt of live attenuated vaccination within 30 days prior to first anticipated dose of TIL.
  • History of allogeneic organ transplant
  • History of primary immunodeficiency
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results. Patients with active systemic infections requiring intravenous antibiotics within 1 week prior to enrollment.
  • Any unresolved toxicity (>CTCAE v5 grade 2) from previous anti-cancer therapy. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy).
  • History of pneumonitis or drug-related inflammatory lung disease.
  • Active or prior documented autoimmune disease within the past 2 years. NOTE: Subjects with vitiligo, Grave's disease, limited site eczema, or limited site plaque psoriasis not requiring systemic treatment (within the past 2 years), or other autoimmune conditions which are not expected to recur, are allowed after approval from the medical monitor or PI.
  • Patients with other prior malignancies must have had a ≥ 2-year disease-free interval, except for: in situ carcinoma of the cervix, in situ ductal carcinoma of the breast, in situ prostate cancer, in situ bladder cancer. These must have been deemed stable and not expected to relapse. In addition, early stage skin cancers, including basal, squamous cell cutaneous carcinoma, and melanoma, are permitted if previously treated with curative intent and not expected to relapse.
  • Women who are pregnant or lactating.
  • The effects of adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) infusion on the developing human fetus are unknown. For this reason, women of child-bearing potential (WOCBP) & men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry & for the duration of study participation & until 4 months after completion of study drug administration. Those who do not agree must be excluded. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. WOCBP are defined as premenopausal women capable of becoming pregnant.
  • Penicillin allergy (Penicillin is used in the manufacturing of the cellular therapy product & therefore patients with a documented penicillin allergy are excluded from the trial) Patients with antibiotic allergies per se are not excluded; although the production of TIL for adoptive transfer includes antibiotics, extensive washing after harvest will minimize systemic exposure to antibiotics. INCLUSION OF WOMEN AND MINORITIES: There are no exclusions by race or ethnicity. This study will enroll both men & women but excludes pregnant & lactating

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.